Journal
ONCOTARGET
Volume 8, Issue 33, Pages 55731-55735Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.18469
Keywords
EIF4F; EIF4A; EIF4E; EIF4G; eukaryotic initiation factors
Categories
Funding
- DOD Career Development Award [CA140437]
- Leukemia Research Foundation
- Louisiana Clinical and Translational Science Center Pilot (NIH) [U54GM104940]
- National Natural Science Foundation of China [81472547, 81672924, 81400164]
- Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai [PWRL2014-01]
- Shanghai Science and Technology Committee funding [16411964800]
- Health Science and Technology Development Fund of Pudong New Area of Shanghai [PKJ2015-Y16]
- CDMRP [CA140437, 793839] Funding Source: Federal RePORTER
Ask authors/readers for more resources
Non-small cell lung cancer (NSCLC) accounts for about 85-90% of lung cancer cases, which represents the leading cause of cancer-related death in the world. The majority of lung cancer patients doesn't respond well to conventional chemo-/radiotherapeutic regimens and have a poor prognosis. The recent introduction of targeted therapy and immunotherapy gives new hopes to NSCLC patients, but their outcome/prognosis is far from satisfactory. The translation initiation EIF4F complex has been shown to play important roles in cancer progression, but its functional role and therapeutic effect in lung cancers especially NSCLC remain largely unknown. In this current review, we summarize recent findings regarding the role of EIF4F complex in NSCLC progression and targeted therapy potentials. We also discuss the unanswered questions and future directions in this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available